Last reviewed · How we verify
placebo to vorinostat
placebo to vorinostat is a Histone deacetylase inhibitor Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Cutaneous T-cell lymphoma.
Vorinostat is a histone deacetylase inhibitor that works by blocking the action of histone deacetylases, leading to the accumulation of acetylated histones and altered gene expression.
Vorinostat is a histone deacetylase inhibitor that works by blocking the action of histone deacetylases, leading to the accumulation of acetylated histones and altered gene expression. Used for Cutaneous T-cell lymphoma.
At a glance
| Generic name | placebo to vorinostat |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This results in the inhibition of cell growth and induction of apoptosis in cancer cells. Vorinostat also has anti-inflammatory properties and can modulate the immune response.
Approved indications
- Cutaneous T-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Thrombocytopenia
- Anemia
Key clinical trials
- Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (PHASE2)
- Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer (PHASE2)
- HDAC Inhibitor Augmentation to Clozapine (EARLY_PHASE1)
- Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) (PHASE3)
- A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) (PHASE1)
- A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) (PHASE2, PHASE3)
- Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE2)
- Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo to vorinostat CI brief — competitive landscape report
- placebo to vorinostat updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about placebo to vorinostat
What is placebo to vorinostat?
How does placebo to vorinostat work?
What is placebo to vorinostat used for?
Who makes placebo to vorinostat?
What drug class is placebo to vorinostat in?
What development phase is placebo to vorinostat in?
What are the side effects of placebo to vorinostat?
What does placebo to vorinostat target?
Related
- Drug class: All Histone deacetylase inhibitor drugs
- Target: All drugs targeting Histone deacetylases
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cutaneous T-cell lymphoma
- Compare: placebo to vorinostat vs similar drugs
- Pricing: placebo to vorinostat cost, discount & access